Diabetic Foot Ulcers (Metabolic Disorder) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers – Drugs In Development, 2021, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 20, 10, 2, 17, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Alan Laboratories Inc

Anterogen Co Ltd

Aposcience AG

Aprogen Inc

APstem Therapeutics Inc

AptaBio Therapeutics Inc

Aurealis Therapeutics AG

Beijing Huafeng Biotechnology Co Ltd

Biofilm Pharma

Blue Blood Biotech Corp

Canton Biotechnologies Inc

Cellics Therapeutics Inc

Cellresearch Corp Pte Ltd

Celularity Inc

Chiesi Farmaceutici SpA

Chrysalis BioTherapeutics Inc

Crescita Therapeutics Inc

CSA Biotechnologies LLC

cStem Regeneration Pharmaceutical Co Ltd

Cynata Therapeutics Ltd

CytoTools AG

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

Genentech USA Inc

Health & Biotech Co Ltd

Helixmith Co Ltd

Hoth Therapeutics Inc

Human Stem Cells Institute

Lakewood-Amedex Inc

Liminal BioSciences Inc

Madam Therapeutics BV

Mallinckrodt Plc

MangoGen Pharma Inc

MediWound Ltd

Mirae Cell Bio Co Ltd

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Orbsen Therapeutics Ltd

Perpetuum BV

Pherecydes Pharma SA

Promore Pharma AB

Qilu Pharmaceutical Co Ltd

Remedor Biomed Ltd

RHEACELL GmbH & Co KG

Riptide Bioscience Inc

SaNOtize Research and Development Corp

Scarless Laboratories Inc

Serodus ASA

Shionogi & Co Ltd

Stempeutics Research Pvt Ltd

TechnoPhage SA

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

Tissuetech Inc

Topadur Pharma AG

Transwell Biotech Co Ltd

USV Pvt Ltd

Vasomune Inc

Venturis Therapeutics Inc

Xenexus Pharmaceuticals Pty Ltd

Zhittya Genesis Medicine Inc

ZZ Biotech LLC

Table of Contents

Table of Contents

Introduction

Diabetic Foot Ulcers - Overview

Diabetic Foot Ulcers - Therapeutics Development

Diabetic Foot Ulcers - Therapeutics Assessment

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development

Diabetic Foot Ulcers - Drug Profiles

Diabetic Foot Ulcers - Dormant Projects

Diabetic Foot Ulcers - Discontinued Products

Diabetic Foot Ulcers - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Diabetic Foot Ulcers – Pipeline by Alan Laboratories Inc, 2021

Diabetic Foot Ulcers – Pipeline by Anterogen Co Ltd, 2021

Diabetic Foot Ulcers – Pipeline by Aposcience AG, 2021

Diabetic Foot Ulcers – Pipeline by Aprogen Inc, 2021

Diabetic Foot Ulcers – Pipeline by APstem Therapeutics Inc, 2021

Diabetic Foot Ulcers – Pipeline by AptaBio Therapeutics Inc, 2021

Diabetic Foot Ulcers – Pipeline by Aurealis Therapeutics AG, 2021

Diabetic Foot Ulcers – Pipeline by Beijing Huafeng Biotechnology Co Ltd, 2021

Diabetic Foot Ulcers – Pipeline by Biofilm Pharma, 2021

Diabetic Foot Ulcers – Pipeline by Blue Blood Biotech Corp, 2021

Diabetic Foot Ulcers – Pipeline by Canton Biotechnologies Inc, 2021

Diabetic Foot Ulcers – Pipeline by Cellics Therapeutics Inc, 2021

Diabetic Foot Ulcers – Pipeline by Cellresearch Corp Pte Ltd, 2021

Diabetic Foot Ulcers – Pipeline by Celularity Inc, 2021

Diabetic Foot Ulcers – Pipeline by Chiesi Farmaceutici SpA, 2021

Diabetic Foot Ulcers – Pipeline by Chrysalis BioTherapeutics Inc, 2021

Diabetic Foot Ulcers – Pipeline by Crescita Therapeutics Inc, 2021

Diabetic Foot Ulcers – Pipeline by CSA Biotechnologies LLC, 2021

Diabetic Foot Ulcers – Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2021

Diabetic Foot Ulcers – Dormant Projects, 2021

Diabetic Foot Ulcers – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports